Tuning the tumor, trafficking the T cell: sIRE opens the door for solid tumor CAR T cells

Effective chimeric antigen receptor (CAR) T cell therapy in solid tumors depends on successful tumor engagement, involving trafficking to tumor sites, intratumoral distribution, and sustained cytotoxic function within the tumor microenvironment. In solid tumors, T cells are frequently excluded from the tumor core and at times remain at the periphery or in the stroma, wherein the extracellular matrix restricts T cell migration within the tumor and limits direct interaction of the tumor and immune cells.